Browsing by Author RAJA C.

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 11 of 11
Publication YearJRC N°TitleAuthor(s), Editor(s), Other Contributor(s)Publication Type
2011JRC65533Analysis of Patient Survival in a Phase 1 Trial of Systemic Targeted Alpha Therapy for Metastatic MelanomaALLEN B. J.; SINGLA A; RAJA C.; RIZVI S.; GRAHAM P.; BRUCHERTSEIFER Frank; APOSTOLIDIS Christos; MORGENSTERN AlfredArticles in Journals
2008JRC48529Bismuth-213 Radioimmunotherapy with C595 Anti¿MUC1 Monoclonal Antibody in an Ovarian Cancer Ascites ModelSONG E.; QU C. F.; RIZVI S.; RAJA C.; BERETOV J.; MORGENSTERN Alfred; APOSTOLIDIS Christos; BRUCHERTSEIFER Frank; PERKINS A. D.Articles in Journals
2008JRC44968The Cytokinesis-Block Micronucleus Assay as a Biological Dosimeter for Targeted Alpha TherapySONG E.; RIZVI S.; QU C. F.; RAJA C.; YUEN J.; LI Y.; MORGENSTERN ALFRED; APOSTOLIDIS CHRISTOS; ALLEN B. J.Articles in Journals
2006JRC33597Cytotoxicity of PAI2, C595 and Herceptin Vectors Labeled with the Alpha-Emitting Radioisotope Bismuth-213 for Ovarian Cancer Cell Monolayers and ClustersSONG Y.j.; QU C.f.; RIZVI S.m.a.; LI Y.; ROBERTSON G.; RAJA C.; MORGENSTERN ALFRED; APOSTOLIDIS CHRISTOS; PERKINS A.c.; ALLEN Barry J.Articles in Journals
2009JRC50507Inhibition ofMicrometastatic Prostate Cancer Cell Spread in Animal Models By 213BilabeledMultipleTargeted Alpha-RadioimmunoconjugatesLI Y.; SONG E.; ABBAS RIZVI S. M.; POWER C. A.; BERETOV J.; RAJA C.; COZZI P. J.; MORGENSTERN Alfred; APOSTOLIDIS Christos; ALLEN B. J., et alArticles in Journals
2007JRC41943Interim Analysis of Toxicity and Response in Phase 1 Trial of Systemic Targeted Alpha Therapy for Metastatic MelanomaRAJA C.; GRAHAM P.; ABBAS RIZVI S. M.; SONG E.; GOLDSMITH H.; THOMPSON J.; BOSSERHOFF A.; MORGENSTERN ALFRED; APOSTOLIDIS CHRISTOS; KEARSLEY J., et alArticles in Journals
2005JRC33607Intralesional Targeted Alpha Therapy for Metastatic MelanomaALLEN Barry J.; RAJA C.; RIZVI S.m.a.; LI Y.; TSUI W.; GRAHAM P.; THOMPSON J.; REISFELD R.a.; KEARSLEY J.; MORGENSTERN ALFRED, et alArticles in Journals
2007JRC41947Pharmacokinetics and toxicity of 213Bi-labeled PAI2 in Preclinical Targeted Alpha Therapy for CancerSONG E.; ABBAS RIZVI S. M.; QU C. F.; RAJA C.; BRECHBIEL M. W.; MORGENSTERN ALFRED; APOSTOLIDIS CHRISTOS; ALLEN B. J.Articles in Journals
2005JRC33606Pre-clinical Study of 213Bi Labeled PAI2 for the Control of Micrometastatic Pancreatic CancerQU C.f.; SONG E.; LI Y.; RIZVI S.m.a.; RAJA C.; ROSS R; APOSTOLIDIS CHRISTOS; ALLEN Barry J.; MORGENSTERN ALFREDArticles in Journals
2006JRC35141Preclinical Studies of Bismuth-213 Labeled Plasminogen Activator Inhibitor Type 2 (PAI2) in a Prostate Cancer Nude Mouse Xenograft ModelRIZVI S.m.a.; LI Y.; SONG E.; QU C.f.; RAJA C.; MORGENSTERN ALFRED; APOSTOLIDIS CHRISTOS; ALLEN B.j.Articles in Journals
2008JRC48531Preparation and Testing of Bevacizumab Radioimmunoconjugates with Bismuth-213 and Bismuth-205 / Bismuth-206RIZVI S.; SONG E.; RAJA C.; BERETOV J.; MORGENSTERN Alfred; APOSTOLIDIS Christos; RUSSELL P. J.; KEARSLEY J.; ABBAS Kamel; ALLEN B. J.Articles in Journals